English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Hyponatremia is a common electrolyte disorder observed in heart failure (HF) patients making it difficult to treat with diruetics. Additionally, HF remains one of the costliest diagnoses in the United States with an estimated cost of around $31 billion for Medicare recipients. Finding an effective and inexpensive treatment becomes imperative to offset these staggering rates. Objective: The objective of this pilot study was to determine the safety of using acetazolamide in healthy individuals and to confirm that its properties would be that of an aquaretic rather than a diuretic. Methods: Baseline serum samples for electrolyte levels and kidney function were obtained. Subjects were then administered 250mg of acetazolamide orally every day for 5 days. On the final day of medication administration, each subject once again repeated the same laboratory tests. Results: Twelve healthy subjects participated. No significant change in urine sodium, urine osmolality, and serum sodium was observed at the completion of the study period. Conclusions: Acetazolamide has been classified as a diuretic, but our study indicates that it may actually act more like an aquaretic. We showed a mild trended increase yet no significant change in serum sodium levels in healthy individuals after five days. Hence, future studies in hypervolemic hyponatremic HF patients may elucidate this medications ability to improve the sodium levels, fluid status and mortality rates cost effectively in this population. *Correspondence to: Teri M Kozik, St. Joseph’s Medical Center, Research Department, 1800 N. California Street, Stockton CA 95204, USA, E-mail: Teri. Kozik@DignityHealth.org

journal of integrative cardiology

Feasibility Study to determine if administration of Carbonic anhydrase inhibitor Acetazolamide (Diamox) will cause aquaresis but prevent hyponatriemia in a healthy population: SALT Study